Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
| Autor: | M. Victoria Pendón-Ruiz de Mier, Mariano Rodriguez, Maria Dolores Arenas, Cristian Rodelo-Haad |
|---|---|
| Přispěvatelé: | [Arenas,MD] Nephrology Department, Vithas Perpetuo Socorro International, Alicante, Spain. [Arenas,MD] Nefrologia Clínica y Dialisis, Consorci Parc de Salut Mar, Barcelona, Spain. [Rodelo-Haad,C, Pendón-Ruiz de Mier,MV, Rodriguez,M] Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain. [Rodelo-Haad,C, Rodriguez,M] Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain. [Rodelo-Haad,C, Rodriguez,M] RETICs-REDinREN (National Institute of Health Carlos III), Madrid, Spain., M.V.P.-R.d.M. is the recipient of a research contract sup ported by the Rio Hortega Programme from the National Institute of Health Carlos III. |
| Rok vydání: | 2020 |
| Předmět: |
Cinacalcet
Calcimimetic medicine.medical_treatment 030232 urology & nephrology Parathyroid hormone Diseases::Endocrine System Diseases::Parathyroid Diseases::Hyperparathyroidism::Hyperparathyroidism Secondary [Medical Subject Headings] 030204 cardiovascular system & hematology Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] 0302 clinical medicine adherence Cumplimiento de la medicación Etelcalcetide etelcalcetide Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Questionnaires [Medical Subject Headings] Chemicals and Drugs::Inorganic Chemicals::Phosphorus Compounds::Phosphorus Acids::Phosphoric Acids::Phosphates [Medical Subject Headings] Chemicals and Drugs::Inorganic Chemicals::Calcium Compounds [Medical Subject Headings] Persons::Persons::Patients [Medical Subject Headings] Nephrology Hormona paratiroidea Pacientes Secondary hyperparathyroidism Hemodialysis medicine.symptom Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques Analytical::Dialysis [Medical Subject Headings] PTH medicine.drug medicine.medical_specialty Urology cinacalcet Asymptomatic Hiperparatiroidismo secundario Calcio 03 medical and health sciences medicine Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy::Renal Dialysis [Medical Subject Headings] AcademicSubjects/MED00340 Transplantation Hyperparathyroidism calcium business.industry Adhesión celular Diálisis Original Articles medicine.disease Chemicals and Drugs::Hormones Hormone Substitutes and Hormone Antagonists::Hormones::Peptide Hormones::Parathyroid Hormone [Medical Subject Headings] Adherence Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Health Behavior::Patient Compliance::Medication Adherence [Medical Subject Headings] Calcium business |
| Zdroj: | Clinical Kidney Journal |
| ISSN: | 2048-8513 |
| DOI: | 10.1093/ckj/sfaa005 |
| Popis: | Background In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. Method The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months. Results Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean ± standard deviation) from 818 ± 395 to 367 ± 289 pg/mL (P Conclusion The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic. The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|